In the past week, IBRX stock has gone up by 10.24%, with a monthly gain of 12.01% and a quarterly plunge of -2.14%. The volatility ratio for the week is 3.53%, and the volatility levels for the last 30 days are 7.23% for ImmunityBio Inc The simple moving average for the past 20 days is 12.39% for IBRX’s stock, with a -18.39% simple moving average for the past 200 days.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
The stock has a 36-month beta value of 0.03. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IBRX is 91.82M, and at present, short sellers hold a 80.31% of that float. On June 02, 2025, the average trading volume of IBRX was 7.84M shares.
IBRX) stock’s latest price update
The stock price of ImmunityBio Inc (NASDAQ: IBRX) has jumped by 4.85 compared to previous close of 2.66. Despite this, the company has seen a gain of 10.24% in its stock price over the last five trading days. businesswire.com reported 2025-06-02 that CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherap.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with Piper Sandler repeating the rating for IBRX by listing it as a “Overweight.” The predicted price for IBRX in the upcoming period, according to Piper Sandler is $5 based on the research report published on May 20, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $8. The rating they have provided for IBRX stocks is “Buy” according to the report published on March 06th, 2025.
BTIG Research gave a rating of “Buy” to IBRX, setting the target price at $6 in the report published on January 10th of the current year.
IBRX Trading at 6.18% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.45% of loss for the given period.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -10.04 for the present operating margin
- 0.87 for the gross margin
The net margin for ImmunityBio Inc stands at -13.1. The total capital return value is set at -1.23.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated -0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -9.13. The debt to equity ratio resting at -0.07. The interest coverage ratio of the stock is -3.09.
Currently, EBITDA for the company is -241.76 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 77.8. The receivables turnover for the company is 1.83for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
To sum up, ImmunityBio Inc (IBRX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
